How do Semaglutide and Tirzepatide differ in their mechanisms for weight loss? – Healthcare Select - MWL

Introduction

Semaglutide and tirzepatide are glucagon-like peptide-1 (GLP-1) receptor agonists that have shown remarkable efficacy in promoting weight loss. Both drugs interact with the GLP-1 receptor, mimicking the effects of the naturally occurring GLP-1 hormone, an incretin hormone released from the intestines after meals that plays a vital role in regulating blood sugar levels and appetite. However, these two medications differ in their mechanisms of action, leading to variations in their weight loss effects. This article offers a comprehensive comparative analysis of semaglutide and tirzepatide, examining their mechanisms for weight loss, clinical trial data, potential side effects, and cost and availability.

Semaglutide

Semaglutide is a GLP-1 receptor agonist with a unique chemical structure that contributes to its long-acting nature. It is a synthetic analog of human GLP-1, with 94% homology to the native hormone. The molecule consists of 31 amino acids, with specific modifications that enhance its stability and efficacy. An alanine residue at the 8th position is substituted with Aib (2-aminoisobutyric acid), which protects semaglutide from enzymatic degradation by DPP-4 2. Additionally, a lysine residue at the 26th position is acylated for attachment with a C18 fatty diacid through a hydrophilic linker. This modification prolongs the systemic half-life of semaglutide by enhancing albumin binding and reducing renal clearance.

Mechanism of Action for Weight Loss

Semaglutide promotes weight loss through several key mechanisms:

Increased Insulin Secretion: Semaglutide binds to and activates GLP-1 receptors in the pancreas, stimulating the release of insulin in response to elevated blood sugar levels. This glucose-dependent insulin secretion helps regulate blood sugar and prevents the storage of excess glucose as fat.
Reduced Glucagon Production: Semaglutide also suppresses the production of glucagon, a hormone that increases blood sugar levels. By reducing glucagon secretion, semaglutide helps lower blood sugar and decreases the body's tendency to store excess glucose as fat.
Slowed Gastric Emptying: Semaglutide slows the rate at which food empties from the stomach, leading to prolonged feelings of fullness and reduced appetite. This effect contributes to a decrease in calorie intake and promotes weight loss.
Action on Brain Appetite Centers: Semaglutide acts on appetite-regulating centers in the brain, specifically by interacting with GLP-1 receptors in the hypothalamus. This interaction promotes a sense of satiety, reduces hunger, and further contributes to decreased food consumption.
Interaction with Leptin: Semaglutide also interacts with the hormone leptin, which plays a crucial role in regulating appetite and energy balance. This interaction further enhances semaglutide's appetite-suppressing effects.

Cardiovascular Benefits

In addition to its weight loss effects, semaglutide has demonstrated cardiovascular benefits. Studies have shown that semaglutide can reduce various cardiovascular risk factors in patients with established cardiovascular disorders. This effect may be attributed to its ability to improve glycemic control, reduce blood pressure, and promote weight loss.

Effects on Adipose Tissue

Semaglutide may also modulate adipose tissue browning, a process that enhances energy expenditure and has potential benefits for metabolism and skeletal muscle degeneration. This effect may be linked to semaglutide's anti-inflammatory, antioxidant, and autophagy-regulating properties.

Anti-inflammatory Effects

Emerging research suggests that semaglutide may have anti-inflammatory effects, potentially protecting against infections and tissue inflammation. This effect may be related to its influence on senescence-associated secretory phenotype (SASP), a complex of factors involved in cellular aging and inflammation.

Tirzepatide

Tirzepatide is a novel GLP-1 receptor agonist that distinguishes itself by also activating the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP, like GLP-1, is an incretin hormone involved in glucose regulation and appetite control. However, tirzepatide exhibits a greater affinity for GIP receptors than for GLP-1 receptors. This dual-receptor activation allows tirzepatide to exert more potent effects on blood sugar and weight loss compared to semaglutide.

Mechanism of Action for Weight Loss

Tirzepatide's weight loss effects are mediated through the following mechanisms:

Dual-Receptor Activation: By activating both GLP-1 and GIP receptors, tirzepatide enhances insulin secretion, reduces glucagon production, and slows gastric emptying. This combined effect leads to improved blood sugar control and greater weight loss compared to semaglutide, which only activates the GLP-1 receptor.
Increased Satiety: Tirzepatide interacts with areas in the brain that regulate appetite, promoting a sense of fullness and reducing hunger. This effect is similar to that of semaglutide but may be amplified by the dual-receptor activation.
Slowed Gastric Emptying: Like semaglutide, tirzepatide slows down the rate at which food empties from the stomach, contributing to feelings of fullness and reduced appetite.
Increased Adiponectin Levels: Tirzepatide has been shown to increase levels of adiponectin, an adipokine involved in regulating glucose and lipid metabolism. This effect may contribute to improved metabolic health and further support weight loss.

Potential Role in Nonalcoholic Fatty Liver Disease

Given its weight loss properties and lack of liver toxicity, tirzepatide may have an indirect role in treating nonalcoholic fatty liver disease. However, further research is needed to confirm this potential benefit.

Cardiovascular Benefits

In addition to its effects on weight and blood sugar, tirzepatide may also lower blood pressure. This effect could have significant implications for cardiovascular health, particularly in individuals with obesity who are at increased risk for hypertension.

Clinical Trial Data

Clinical trials have provided compelling evidence for the superiority of tirzepatide over semaglutide in promoting weight loss. In the SURMOUNT-5 trial, which included adults with obesity or overweight with weight-related comorbidities but without type 2 diabetes, participants who received tirzepatide achieved an average weight loss of 20.2% over 72 weeks, compared to 13.7% with semaglutide. Another study, SURMOUNT-4, investigated the effects of tirzepatide discontinuation and found that participants regained a significant amount of weight within a year of stopping the medication. This finding highlights the importance of ongoing treatment with tirzepatide to maintain weight loss.

Comparative Analysis

Feature	Semaglutide	Tirzepatide
Receptor Activation	GLP-1 receptor	GLP-1 and GIP receptors
Average Weight Loss	15% (72 weeks)	20.2% (72 weeks)
Key Mechanisms	Increased insulin secretion, reduced glucagon production, slowed gastric emptying, action on brain appetite centers, interaction with leptin	Dual-receptor activation, increased satiety, slowed gastric emptying, increased adiponectin levels
Side Effects	Nausea, vomiting, diarrhea, constipation, headache, dizziness, fatigue	Nausea, vomiting, diarrhea, constipation, headache, dizziness, fatigue

Both semaglutide and tirzepatide slow gastric emptying, contributing to feelings of fullness and reduced appetite. This shared mechanism is a key factor in their weight loss effects. However, the key difference lies in their receptor activation profiles. Semaglutide acts solely on the GLP-1 receptor, while tirzepatide activates both GLP-1 and GIP receptors. This dual-receptor activation appears to be responsible for tirzepatide's greater weight loss efficacy compared to semaglutide.

13. Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% | Eli Lilly and Company, accessed February 10, 2025, https://investor.lilly.com/news-releases/news-release-details/lillys-zepboundr-tirzepatide-superior-wegovyr-semaglutide-head

14. Tirzepatide Enhances Weight Loss with Sustained Treatment but Discontinuation Leads to Weight Regain | Newsroom | Weill Cornell Medicine, accessed February 10, 2025, https://news.weill.cornell.edu/news/2023/12/tirzepatide-enhances-weight-loss-with-sustained-treatment-but-discontinuation-leads-to

15. Semaglutide (subcutaneous route) - Mayo Clinic, accessed February 10, 2025, https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/description/drg-20406730

16. Tirzepatide (subcutaneous route) - Mayo Clinic, accessed February 10, 2025, https://www.mayoclinic.org/drugs-supplements/tirzepatide-subcutaneous-route/description/drg-20534045

17. How Much Does Semaglutide Cost With and Without Insurance? - Ro, accessed February 10, 2025, https://ro.co/weight-loss/how-much-does-semaglutide-cost/

18. Is Tirzepatide Affordable Without Insurance? | Blog - Genesis Lifestyle Medicine, accessed February 10, 2025, https://www.genesislifestylemedicine.com/blog/is-tirzepatide-affordable-without-insurance/

19. Ozempic (semaglutide) shortage collection | Therapeutic Goods Administration (TGA), accessed February 10, 2025, https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/ozempic-semaglutide-shortage-2022-2025/ozempic-semaglutide-shortage-collection

20. www.goodrx.com, accessed February 10, 2025, https://www.goodrx.com/classes/gip-receptor-glp-1-receptor-agonists/tirzepatide-shortage#:~:text=Tirzepatide%20is%20an%20injectable%20medication,tirzepatide%20injection%20shortage%20was%20resolved.

Introduction

Semaglutide

Mechanism of Action for Weight Loss

Cardiovascular Benefits

Effects on Adipose Tissue

Anti-inflammatory Effects

Tirzepatide

Mechanism of Action for Weight Loss

Potential Role in Nonalcoholic Fatty Liver Disease

Cardiovascular Benefits

Clinical Trial Data

Comparative Analysis

Further Reading